Polycystic Ovarian Syndrome Treatment Market Research Report 2026: Effect Factors Analysis, Driving Force, Constraints and Threat Prediction
Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1589
Polycystic Ovarian Syndrome Treatment Market – Driver:
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.). The acquisition will expand Astellas’ clinical pipeline with fezolinetant, oral compaound for NK3 receptor target. Fezolinetant was in phase IIa clinical trials for the treatment of menopausal hot flashes, polycystic ovary syndrome (PCOS) and uterine fibroids. Moreover, product approval by various approval bodies will expand the treatment option and in turn leading to the market growth. For instance, in 2014, EffRx Pharmaceuticals SA, got US FDA approval for its proprietary metformin-based product candidate, EX404, for pediatric polycystic ovary syndrome (PCOS).
Increasing funding for research and development of novel treatment will also enhance the polycystic ovarian syndrome treatment market during the forecast period. For instance, in 2017, Bayer and the Society for Reproductive Investigation (SRI) launched of the SRI-Bayer Discovery and Innovation Grants Program for supporting research initiatives for addressing unmet medical needs in women’s health. The grant is dedicated to research in endometriois, uterine fibroids and polycystic ovarian syndrome. Further, grants for the treatment of polycystic ovarian syndrome will fuel the market growth. For instance, in 2017, as part of a multi-year endowment from PCOS Diva, the nonprofit organization PCOS Challenge, Inc. will be offering grants up to $500 to help women and girls struggling with hair and skin issues related to polycystic ovary syndrome (PCOS).
Polycystic Ovarian Syndrome Treatment Market - Regional Analysis:
Regional segmentation of polycystic ovarian syndrome treatment market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America market is expected to emerge as the dominant market for polycystic ovary syndrome treatment market owing to a high diagnosis rate, larger number of local players such as AstraZeneca, Teva etc. and high prevalence of the polycystic ovarian syndrome in the region. Asia Pacific is expected to witness fast growth during the forecast period attributing to high population of risk prone individuals.
Polycystic Ovarian Syndrome Treatment Market – Competitor:
• Accord Healthcare Ltd.
• Teva Pharmaceutical Industries Ltd.
• Eisai Pharmaceuticals India Pvt. Ltd (EIL)
• VIVUS, Inc.
• SkinMedica, Inc. (part of Allergan, Inc.)
• Ferring Pharmaceuticals Inc.
• AstraZeneca plc
• EffRx, Inc.
Polycystic Ovarian Syndrome Treatment Market – Taxonomy:
By Drug Type
• Oral Contraceptives
◦ Other Oral Contraceptives
• Insulin-sensitizing Agent
◦ Other Insulin-sensitizing Agents
• Anti-obesity Drugs
◦ Other Anti-Obesity Drugs
By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
Inquire Here Before Purchase Of This Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1589
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Polycystic Ovarian Syndrome Treatment Market Research Report 2026: Effect Factors Analysis, Driving Force, Constraints and Threat Prediction here
News-ID: 1494729 • Views: 335
More Releases from Coherent Market Insights - Pharmaceutical Industry
Radiopharmaceuticals in Nuclear Medicine Market Advancements to Watch Out For 20 …
Coherent Market Insights released a new market study on 2018-2026 Radiopharmaceuticals Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Ask For Sample Copy of Research
Outsourced Drug Discovery Market: Latest Advancements & Market Outlook 2019 to 2 …
Outsourced drug discovery is a contract-based process, which is conducted by the contract research organizations (CRO) and contract manufacturing organization (CMO). Contract research organization provides support to pharmaceutical, biotechnology, and medical device industries for drug discovery and development. CRO facilitates the various services such as biopharmaceutical development, biologic assay development, preclinical research, clinical trials, and pharmacovigilance, for drug discovery and development. Ask For a Sample Copy of This Business Report @
Cannabis Testing Services Market: New Business Opportunities and Investment Rese …
Cannabis market is highly influenced by rigorous legalization efforts, which are aiming for approval of cannabis for medicinal or recreational purpose. Various governments and regulatory authorities are taking efforts to legalize cannabis, owing to its medicinal benefits. Moreover, commercialization of cannabis-based products under the legalized standards require successful cannabis testing, which further results in lucrative growth opportunity for market players. Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2976 Market
Global Myelodysplastic Syndrome (MDS) Treatment Market Balenced To Reach Insigni …
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around
More Releases for Polycystic
Polycystic Kidney Disease Treatment Comprehensive Analysis and Future Estimation …
According to Fact.MR, Insights of Polycystic Kidney Disease Treatment is a specialized and in-depth study of the industry with a special focus on the Key Trends of Polycystic Kidney Disease Treatment as a Service. The report aims to provide an overview with detailed segmentation by type, application, end use and geography. The global is expected to witness high growth during the forecast period. A survey offers detailed analysis on key growth
Polycystic Ovarian Syndrome Treatment Market Report
The findings reviewed by GME stated that the Global Polycystic Ovarian Syndrome Treatment Market will expand with a CAGR value of 5.2 percent from 2021 to 2026. The rising incidence of PCOS increased understanding among a group of patients, and the growing acceptance of standard treatment boosts the PCOS treatment industry growth over the projected timeframe. Furthermore, the research and development of PCOS are predicted to aid in market growth. Browse
Polycystic Ovarian Syndrome Treatment Market - Regional Analysis
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.).
Polycystic Ovarian Syndrome - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Polycystic Ovarian Syndrome - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Ovarian Syndrome - Pipeline Review, H2 2017, provides an overview of the Polycystic Ovarian Syndrome (Women's Health) pipeline landscape. Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms
Polycystic kidney disease Pharmaceutical and Healthcare Pipeline Review H2
Summary Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics. Report Highlights Pharmaceutical and Healthcare latest pipeline guide Polycystic Kidney Disease - Pipeline Review, H2 2017, provides comprehensive information on
Polycystic Ovary Syndrome Treatment Market Estimated to Flourish by 2024
Growth of the global polycystic ovary syndrome drugs market is mainly driven by increasing prevalence of the disease and a growing awareness among the patient population. Increasing purchasing power among people and rising awareness of PCOS are factors expected to drive growth of the global PCOS drugs market. The need for effective management of diseases associated with PCOS such as hirsutism, obesity, and infertility is likely to boost the demand